Neisserial PorB immune enhancing activity and use as a vaccine adjuvant

References

• Vaccine Adjuvants | NIH: National Institute of Allergy and Infectious Diseases. 2018 [accessed 12 Mar 2019] https://www.niaid.nih.gov/research/vaccine-adjuvants.
   Google Scholar
• Di Pasquale A, Preiss S, Tavares Da Silva F, Garçon N. Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines. 2015;3(2):320–43. doi:10.3390/vaccines3020320.
   PubMed Web of Science ®Google Scholar
• Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9(4):287–93. doi:10.1038/nri2510.
   PubMed Web of Science ®Google Scholar
• Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20(1):197–216. doi:10.1146/annurev.immunol.20.083001.084359.
   PubMed Web of Science ®Google Scholar
• Massari P, Henneke P, Ho Y, Latz E, Golenbock DT, Wetzler LM. Cutting edge: immune stimulation by Neisserial porins is toll-like receptor 2 and MyD88. J Immunol. 2002;168(4):1533–37. doi:10.4049/jimmunol.168.4.1533.
   PubMed Web of Science ®Google Scholar
• Massari P, Visintin A, Gunawardana J, Halmen KA, King CA, Golenbock DT, Wetzler LM. Meningococcal porin PorB binds to TLR2 and requires TLR1 for signaling. J Immunol. 2006;176(4):2373–80. doi:10.4049/jimmunol.176.4.2373.
   PubMed Web of Science ®Google Scholar
• Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19(12):1597–608. doi:10.1038/nm.3409.
   PubMed Web of Science ®Google Scholar
• Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol. 2013;4:114. doi:10.3389/fimmu.2013.00114.
   PubMed Web of Science ®Google Scholar
• Kostova D, Reed C, Finelli L, Cheng PY, Gargiullo PM, Shay DK, Singleton JA, Meltzer MI, Lu PJ, Bresee JS. Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005–2011. PLoS One. Goldstein E, ed. 2013;8(6):e66312. doi:10.1371/journal.pone.0066312.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 – an innately attractive adjuvant formulation. Vaccine. 2012;30(29):4341–48. doi:10.1016/J.VACCINE.2011.09.061.
   PubMed Web of Science ®Google Scholar
• Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine. 2011;29(13):2461–73. doi:10.1016/j.vaccine.2011.01.011.
   PubMed Web of Science ®Google Scholar
• Kim J, Li WA, Choi Y, Lewin SA, Verbeke CS, Dranoff G, Mooney DJ. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat Biotechnol. 2015;33(1):64–72. doi:10.1038/nbt.3071.
   PubMed Web of Science ®Google Scholar
• Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 2011;10(4):499–511. doi:10.1586/erv.10.174.
   PubMed Web of Science ®Google Scholar
• Liu H, Moynihan KD, Zheng Y, Szeto GL, Li AV, Huang B, Van Egeren DS, Park C, Irvine DJ. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014;507(7493):519–22. doi:10.1038/nature12978.
   PubMed Web of Science ®Google Scholar
• Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta - Mol Cell Res. 2002;1589(1):1–13. doi:10.1016/S0167-4889(01)00182-3.
   PubMed Web of Science ®Google Scholar
• Jiang W, Lederman MM, Harding CV, Rodriguez B, Mohner RJ, Sieg SF. TLR9 stimulation drives naïve B cells to proliferate and to attain enhanced antigen presenting function. Eur J Immunol. 2007;37(8):2205–13. doi:10.1002/eji.200636984.
   PubMed Web of Science ®Google Scholar
• Rahman AH, Taylor DK, Turka LA. The contribution of direct TLR signaling to T cell responses. Immunol Res. 2009;45(1):25–36. doi:10.1007/s12026-009-8113-x.
   PubMed Web of Science ®Google Scholar
• Gelman AE, Zhang J, Choi Y, Turka LA. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol. 2004;172(10):6065–73. [accessed 7 Feb 2019]. http://www.ncbi.nlm.nih.gov/pubmed/15128790.
   PubMed Web of Science ®Google Scholar
• Hou B, Reizis B, DeFranco AL. Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. Immunity. 2008;29(2):272–82. doi:10.1016/J.IMMUNI.2008.05.016.
   PubMed Web of Science ®Google Scholar
• Massari P, King CA, MacLeod H, Wetzler LM. Improved purification of native meningococcal porin PorB and studies on its structure/function. Protein Expr Purif. 2005;44(2):136–46. doi:10.1016/J.PEP.2005.04.021.
   PubMed Web of Science ®Google Scholar
• Singleton TE, Massasri P, Wetzler LM. Neisserial porin-induced dendritic cell activation is MyD88 and TLR2 dependent. J Immunol. 2005;176(9):3545–50. doi:10.4049/jimmunol.174.6.3545.
   Google Scholar
• Platt A, MacLeod H, Massari P, Liu X, Wetzler L. In vivo and in vitro characterization of the immune stimulating activity of the neisserial porin PorB. Das G, ed. PLoS One. 2013;8(12):e82171. doi:10.1371/journal.pone.0082171.
   PubMed Web of Science ®Google Scholar
• Mosaheb MM, Reiser ML, Wetzler LM. Toll-like receptor ligand-based vaccine adjuvants require intact MyD88 signaling in antigen-presenting cells for germinal center formation and antibody production. Front Immunol. 2017;8:225. doi:10.3389/fimmu.2017.00225.
   PubMed Web of Science ®Google Scholar
• Reiser ML, Mosaheb MM, Lisk C, Platt A, Wetzler LM. The TLR2 binding neisserial porin PorB enhances antigen presenting cell trafficking and cross-presentation. Sci Rep. 2017. doi:10.1038/s41598-017-00555-4.
   Web of Science ®Google Scholar
• Mosaheb M, Wetzler LM. Meningococcal PorB induces a robust and diverse antigen specific T cell response as a vaccine adjuvant. Vaccine. 2018;36(50):7689–99. doi:10.1016/J.VACCINE.2018.10.074.
   PubMed Web of Science ®Google Scholar